Started
in Lithuania.
Built for
the world.
Leadership
The work requires deep scientific fluency. More than 70% of our team holds a scientific degree — because understanding the biology is a prerequisite for improving the tools.
Nainys, PhD
Chief Executive Officer
Jankevičius
Officer
Ropp, PhD
Officer
Leonavičius, PhD
Technology Officer
Žilionis, PhD
Chief Scientific Officer
Gegevičius
& Chief of Staff
Žepnickaitė
Production
Mažutis, PhD
Scientific Advisor
The Atrandi Story
Founded as Droplet Genomics in 2016, Atrandi grew from years spent at the intersection of engineering and biology – close enough to the limits of existing tools to understand exactly where they failed. Running multi-step workflows within droplets meant constant compromises between compatibility, control, and performance. Semi-Permeable Capsule technology was developed to solve that specific problem. By isolating single cells while allowing reagents to move freely, SPCs made it possible to run complex multi-step workflows under optimal conditions – something no existing system could do. What began as a technical solution became a new way to think about single-cell analysis entirely.
When the potential became clear, the decision was straightforward: this needed to exist beyond the lab. That instinct – to share, to enable, to build something that lets other scientists do work that wouldn’t otherwise be possible – is still the reason Atrandi exists. The company has grown, the platform has expanded, and the applications have multiplied. The most important discoveries are still ahead.
A team of scientists and engineers establishes Droplet Genomics – bringing together deep expertise in droplet microfluidics with a mission to transform how single-cell research is done.
The first Atrandi instrument enters the market, giving researchers precise control over droplet generation with real-time high-speed imaging for custom microfluidic workflows.
The foundational Semi-Permeable Capsule (SPC) technology paper is published in collaboration with Vilnius University – establishing the scientific basis for a new class of single-cell analysis technology.
A high-throughput droplet sorting platform designed for function-based screening – making applications like protein engineering, strain engineering, and others accessible at scale.
A new name to reflect a broader vision – enabling the full landscape of single-cell discovery.
SPC technology becomes globally accessible, empowering researchers to develop novel single-cell workflows beyond established methods.
SPC-powered single-cell encapsulation becomes accessible to any lab –no microfluidics expertise required, up to 100,000 cells in 30 minutes.
Atrandi closes a $25M Series A financing round with Lux Capital (USA), Vsquared (Germany), Practica Capital (Lithuania), Metaplanet (Estonia), and GRIDS Capital (Brazil) — accelerating commercial expansion into the US and deepening the product portfolio.
Mission
The questions that matter most in biology require more than incremental gains. They demand more resolution, more cells, and more layers of information from the same experiment – and the freedom to design workflows around the biology, not around the platform.
Vision
The life sciences are entering a new era. The tools to answer questions that were unanswerable a generation ago are being built right now – and the data they generate is changing how we understand life at its most fundamental level. We are still at the beginning. The complexity of biology is not a barrier. It is the point.
Whether you want to collaborate, join us
or understand what SPC technology could do for your research – the conversation starts here.